الحصن الحصين البيطرية
This shortcode is only available on vendor store pages.
Theil-Cure injection | Buparvaquone | anti theileriosis | cattle
for veterinary use only with a prescription
Theil Cure injection, Buparvaquone, best treatment of theileriosis in cattle
Composition
Each 1ml Theil-Cure injection contains
Buparvaquone —————–50 mg
Properties
Buparvaquone is a hydroxynaphthoquinones which has a specific anti-theilerial action
Theileria spp. is a parasite occurs within lymphocytic and erythrocytic cells and is transmitted by the bites of various species of ticks
The mode of action of Buparvaquone against theileria is thought to be interfering with electron transport within mitochondria at the ubiquinone level
intraerythrocytic piroplasms and could be used in the incubation period or in the clinical phase of the disease It acts on the macroschizonts and
Indications
-Theil Cure injection is indicated for the treatment of theileriosis ( East coast fever ) in cattle caused by Theileria parva sensitive to buparvaquone
– indicated for the treatment of Mediterranean coast fever in cattle caused by Theileria annulata sensitive to buparvaquone
Dose
By I/M route
Cattle
1 ml of Theil-Cure injection per 20 kg body weight by deep I/M injection as a single dose
In severe cases, another injection with the same dose may be needed after 2 – 3 days of the first injection
Contra-indication and Warnings
Do not inject it I/V or S/C
Side-effects
Localized, painless, oedematous, swelling may occasionally be seen at the injection site especially in thin-skinned animals
Withdrawal periods
Cattle Meat: 42 days
Milk: 48 hours
Storage
Store at temperature not exceeding 30°C & use immediately after opening
Vendor Information
- Store Name: الحصن الحصين البيطرية
- Vendor: الحصن الحصين البيطرية
- Address: Riyadh
- No ratings found yet!
Related Products
VERMECTIN injectable soln. | veterinary ivermectin | Livestock
40 ر.س This product has multiple variants. The options may be chosen on the product page
-
In stock (2)
Reviews
There are no reviews yet.